Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice - Concepedia

Concepedia

Publication | Open Access

Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice

DOI Full Paper Access

89

Citations

16

References

2019

Year

Lindsey E. Roeker, Christopher P. Fox, Toby A. Eyre, Danielle M. Brander, John N. Allan, Stephen J. Schuster, Chadi Nabhan, Brian T. Hill, Nirav N. Shah, Frederick Lansigan,

Clinical Cancer Research

Abstract

These data provide insights into current use of venetoclax in clinical practice, including TLS rates observed in clinical practice. We identified opportunities for improved adherence to TLS risk stratification and prophylaxis, which may improve safety.

References

	Year	Citations

Page 1